Efficacy and Safety of Oral 5-FU Derivatives After Progression of HR(+)/HER2(-) Metastatic Breast Cancer on CDK4/6 Inhibitor. Koi Y, Tajiri W, Kawasaki J, Akiyoshi S, et al. Anticancer Res 2025;45:5609-5618.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Koi Y, Tajiri W, Kawasaki J, Akiyoshi S, et al. Efficacy and Safety of Oral 5-FU Derivatives After Progression of HR(+)/HER2(-) Metastatic Breast Cancer on CDK4/6 Inhibitor. Anticancer Res 2025;45:5609-5618.
PMID: 41318158